Unaudited financial (Consolidated and Standalone)results for the quarter ended 30th September, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.9 pts less than Nifty Microcap 250 and 2.0 pts less than its Other Agricultural Products peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Indrayani Biotech reported consolidated Q2 FY26 revenue of ₹3,774.98 lakhs, up roughly 25% from ₹3,015.99 lakhs in Q2 FY25. For the half year, consolidated revenue rose about 8% to ₹6,790.97 lakhs from ₹6,268.65 lakhs. On the profit front, the company swung back to a consolidated profit after tax of ₹106.87 lakhs in H1 FY26, compared with a loss of ₹610.75 lakhs in H1 FY25 — a clear turnaround driven by subsidiaries. Standalone numbers were weaker, with H1 FY26 PAT at ₹59.60 lakhs versus ₹64.63 lakhs a year ago. Operating cash flow was negative on both bases (standalone -₹1,011.84 lakhs, consolidated -₹1,017.20 lakhs), reflecting higher working capital needs. Statutory auditors Venkatesh & Co issued an unmodified (clean) review opinion.
Short-term positive from the revenue rebound and consolidated return to profit, but negative operating cash flows and a slight dip in standalone earnings temper the picture. The director resignation appears routine and the BSE fine for delayed compliance officer appointment (already paid) is a minor governance flag rather than a material issue.